Latest News for 09/2021
17 May 2021
Collaborative research between scientists in the Division of Cell Signalling and Immunology and the University of Leeds has been published in eLife. The work highlights a new cytokine signalling model that helps to understand how cytokine responses become dysregulated and contribute to the development of autoimmune diseases – such as Systemic Lupus Erythematosus.
22 Dec 2020
Cytokines play a crucial role overseeing the correct functioning of the immune system. Interleukin-6 (IL-6) is a critical immune-modulatory cytokine that helps to initiate and sustain the inflammatory response. The IL-6–Janus kinase (JAK)–STAT3 signalling is important for cancers resulting from the activation of the intrinsic inflammatory pathway. Yet, despite its relevancy for human health, we have a poor understanding of how IL-6 elicits its pleiotropic activities.
16 Sep 2020
Latest research led by Ignacio Moraga’s lab in the School has shown how binding affinity is key to anti-inflammatory protein Interleukin-10’s (IL-10) biological effects. This work is published today in Science Signaling.
10 Feb 2020
New research has deciphered how rogue communications in blood stem cells can cause Leukaemia. The discovery, published in the journal Science, could pave the way for new, targeted medical treatments that block this process. Blood cancers like leukaemia occur when mutations in stem cells cause them to produce too many blood cells.
14 Jan 2020
Researchers in the Moraga group report the engineering of new tools to manipulate the immune response with the potential to treat human disorders. The research was done in collaboration with the Kazemian group (Purdue University, USA) and Mitra group (Centre de Recherche Jean-Pierre Aubert, France). The research was published in the journal eLife.
14 Apr 2017
Dr Ignacio Moraga has been awarded €1.7 million to investigate the role that communication between cells plays in autoimmune diseases. The prestigious European Research Council (ERC) starting grant will fund his research over the next five years. Dr Moraga and his team are studying immune response action in the hope of designing better medicines for conditions such as lupus, arthritis and other debilitating autoimmune diseases.